Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease

A. Schäfer,J. Bauersachs,M. Eigenthaler

Published 2009 in Vascular Disease Prevention

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2009
Venue
Vascular Disease Prevention
Publication date
2009-03-20
Fields of study
Medicine
Identifiers
DOI 10.2174/1567270000906010075
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Cell Adhesion Mechanisms in Platelets
2008cited by this paper
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
2008cited by this paper
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15].
2008cited by this paper
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
2007cited by this paper
Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer--comparison with two flow cytometric methods.
2007cited by this paper
Inhibition of platelet glycoprotein Ib and its antithrombotic potential.
2007cited by this paper
First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers
2007cited by this paper
Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study
2007cited by this paper
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
2007cited by this paper
Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance
2007cited by this paper
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
2007cited by this paper
Local vascular dysfunction after coronary paclitaxel-eluting stent implantation.
2007cited by this paper
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007cited by this paper
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ?
2007cited by this paper
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases
2007cited by this paper
Focused Update of the ACC / AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
2007cited by this paper
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.
2007cited by this paper
Platelet integrin alpha(IIb)beta(3): activation mechanisms.
2007cited by this paper
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
2007cited by this paper
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
2007cited by this paper
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D
2007cited by this paper
The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time
2007cited by this paper
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
2007cited by this paper
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
2007cited by this paper
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
2007cited by this paper
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
2006cited by this paper
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
2006cited by this paper
Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function
2006cited by this paper
CLINICAL RESEARCH Interventional Cardiology Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention Insights Into the STRATEGY Study
2006cited by this paper
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006cited by this paper
Aspirin and clopidogrel resistance: consideration and management.
2006influential reference
Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor.
2006cited by this paper
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).
2006cited by this paper
Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All?
2006cited by this paper
Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
2006cited by this paper
FOCUS ISSUE: CARDIAC INTERVENTION Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting
2006cited by this paper
Response to aspirin and clopidogrel monitored with different platelet function methods
2006cited by this paper
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
2006cited by this paper
Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis--a case report and review of the literature.
2006cited by this paper
Quantifying the Effect of Antiplatelet Therapy: A Comparison of the Platelet Function Analyzer (PFA-100®) and Modified Thromboelastography (mTEG®) with Light Transmission Platelet Aggregometry
2006cited by this paper
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
2006cited by this paper
Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
2006cited by this paper
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
2006cited by this paper
Variability in responsiveness to clopidogrel in patients with intermittent claudication.
2006cited by this paper
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
2006cited by this paper
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
2006cited by this paper
Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
2006cited by this paper
Regulation of platelet functions by P2 receptors.
2006cited by this paper
Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress.
2006cited by this paper
Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis
2006cited by this paper
Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists
2005cited by this paper
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
2005cited by this paper
Monitoring of clopidogrel action: comparison of methods.
2005cited by this paper
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
2005cited by this paper
Late angiographic stent thrombosis (LAST) events with drug-eluting stents.
2005cited by this paper
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.
2005cited by this paper
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
2005influential reference
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
2005influential reference
Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.
2005influential reference
The platelet P2 receptors in thrombosis.
2005cited by this paper
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
2005cited by this paper
Integrins: dynamic scaffolds for adhesion and signaling in platelets.
2004cited by this paper
Clopidogrel resistance: a new chapter in a fast-moving story.
2004cited by this paper
Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium.
2004cited by this paper
Oral GPIIb/IIIa antagonists: what went wrong?
2004cited by this paper
Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance
2004cited by this paper
Variable extent of clopidogrel responsiveness in patients after coronary stenting
2004cited by this paper
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
2004cited by this paper
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
2004influential reference
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part I
2003cited by this paper
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part II
2003cited by this paper
Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity
2003cited by this paper
Both the ADP receptors P2Y 1 and P2Y 12 , play a role in controlling shape change in human platelets
2003cited by this paper
Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects
2003cited by this paper
Scientific and therapeutic advances in antiplatelet therapy
2003cited by this paper
Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylation
2003cited by this paper
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement
2003cited by this paper
Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects
2003cited by this paper
Platelets in atherothrombosis
2002cited by this paper
Individual variations of platelet inhibition after loading doses of clopidogrel
2002cited by this paper
Identification and Biological Activity of the Active Metabolite of Clopidogrel
2000cited by this paper
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.
2000cited by this paper
Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.
2000cited by this paper
Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
1999cited by this paper
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.
1999cited by this paper
Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets
1999cited by this paper
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
1998cited by this paper
Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors
1998cited by this paper
Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.
1998cited by this paper
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
1996cited by this paper
The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy.
1995cited by this paper
Description of an In Vitro Platelet Function Analyzer-PFA-100™
1995cited by this paper
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.
1983cited by this paper

CITED BY